Linda C. Burkly - 28 Jul 2026 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: EVP, CHIEF SCIENTIFIC OFFICER
Issuer ticker: EDIT
Reported as of: 28 Jul 2026
Net transaction value: -$13,158
SEC form: 4
Accepted by SEC: 29 Jul 2026, 16:51:02 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Linda C. Burkly

Key filing fact

Linda C. Burkly filed Form 4 for Editas Medicine, Inc. (EDIT) on 29 Jul 2026.

Key facts

This page summarizes Linda C. Burkly's Form 4 filing for Editas Medicine, Inc. (EDIT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Jul 2026, 16:51.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$13,158.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001985604 Primary reporting owner

Burkly Linda

Relationship: EVP, CHIEF SCIENTIFIC OFFICER
Address: 11 HURLEY ST., CAMBRIDGE
Signature: /s/ Linda C. Burkly
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Sale

Transaction value: $13,158
Shares: -4,928
Change %: -7.3%
Price: $2.67
Shares after: 62,369
Date: 28 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2026. The sale does not represent a discretionary trade by the Reporting Person.